The HIV epidemic associated with injecting drug use in Europe: Geographic and time trends

AIDS

Volumn 11, Issue 11, 1997, Pages 1365-1374

  Hamers, Françoise F ^a,b   Batter, Véronique ^a   Downs, Angela M ^a   Alix, Jane ^a   Cazein, Françoise ^a   Brunet, Jean Baptiste ^a  

^a Europ Ctr Epidemiol Monitoring A   (France)

^b Hospital National de Saint Maurice   (France)

Author keywords

AIDS; Europe; HIV; Incidence; Injecting drug; Prevalence; User

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTICLE; CHILD; EASTERN EUROPE; EUROPE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INCIDENCE; INTRAVENOUS DRUG ABUSE; ITALY; MAJOR CLINICAL STUDY; MALE; PORTUGAL; PRIORITY JOURNAL; SPAIN; UKRAINE; USSR;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGE FACTORS; AGED; BISEXUALITY; CHILD; CHILD, PRESCHOOL; DISEASE OUTBREAKS; DISEASE TRANSMISSION, VERTICAL; EUROPE; FEMALE; HIV INFECTIONS; HIV SEROPREVALENCE; HOMOSEXUALITY, MALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PREVALENCE; SEXUAL BEHAVIOR; SEXUAL PARTNERS; SUBSTANCE ABUSE, INTRAVENOUS; WORLD HEALTH ORGANIZATION;

EID: 0030880298     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199711000-00011     Document Type: Article

References (76)

1. European Centre for the Epidemiological Monitoring of AIDS: HIV/AIDS Surveillance in Europe. Quarterly Report No. 49. Saint-Maurice: European Centre for the Epidemiological Monitoring of AIDS; 1996.
2. Robertson JR, Bucknall ABV, Welsby PD, et al.: Epidemic of AIDS related virus (HTLV-III/LAV) infection among intravenous drug abusers. BMJ 1986, 292:527-529.
3. Rezza G, Nicolosi A, Zaccarelli M, et al.: Understanding the dynamics of the HIV epidemic among Italian intravenous drug users: a cross-sectional versus a longitudinal approach. J Acquir Immune Defic Syndr 1994, 7:500-503
4. Sopelana P, Dieguez A, Bautista I : Prevalence of human immunodeficiency virus type 1 infection among drug addicts in Madrid, during a 5-year period [in Spanish]. Med Clin (Barc) 1991, 97:601-603
5. Rebagliato M, Avino MJ, Herandez-Aguado I, et al.: Trends in incidence and prevalence of HIV-1 infection in intravenous drug users in Valencia, Spain. J Acquir Immun Defic Syndr 1995, 8:297-301.
6. Stark K, Wirth D, Sieroslawski J, Godwod-Sikorska C, Mueller R: High HIV seroprevalence in injecting drug users in Warsaw, Poland. J Acquir Immun Defic Syndr 1994, 7:877-878.
7. Kilibarda M: HIV infection among drug abusers in the Belgrade area. Bull Narc 1993, 45:135-146.
8. Kobyshcha Y, Sheherbinskaya A, Khodakevich I, Andrushchak L, Kruglov Y: HIV infection among drug users in Ukraine: beginning of the epidemic. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuC204].
9. Ingram M: Russia is on brink of AIDS epidemic. BMJ 1996, 313:252.
10. Heisterkamp SH, Jager JC, Downs AM, Van Druten JA, Ruitenberg H: Correcting reported AIDS incidence: a statistical approach. Stat Med 1989, 8:963-976.
11. United Nation Population Division: World Population Prospect: 1994 Revision. New York: UN: 1994.
12. Iodts S, Avonts D, Vercauleren G, Piot P: HIV seroprevalence and risk behaviour in IV drug users in a low HIV prevalence city in Belgium. VI Intrnational Conference on AIDS. San Francisco, June 1990 [abstract FC618].
13. Worm AM, Gollschau A: No change in incidence and prevalence of HIV among intravenous drug users in Copenhagen from 1985 to 1990. J Acquir Immun Defic Syndr 1993, 6:845-848.
14. Leinikki P, Lillsunde P, Kantannen MI , Korte T, Seppälä I: Virus infections associated with injecting drug abuse [in Finnish]. Duodecim 1996, 112:150-155.
15. van den Hoek JAR, van Haastrecht HJ, van Zadelhoff WA, Goudsmit J, Coutinho RA: HIV infection among drug users in Amsterdam: prevalence and risk factors [in Dutch]. Ned Tijdschr Geneeskd 1988, 132:723-728.
16. van Haastrecht HJ, van den Hoek JAR, Bardoux C, Leentvaar-Kuypers A, Coutinho RA: The course of the HIV epidemic among intravenous drug users in Amsterdam, the Netherlands. Am J Public Health 1991, 81:59-62.
17. Lennema JS, van Ameijden EJ, van den Hoek JAR, van den Akker R, Coutinho RA: HIV prevalence among intravenous drug users in Amsterdam; study on the street [in Dutch]. I Soc Gezondheidsz 1993, 71:267-272.
18. Richardson C, Ancelle-Park R, Papaevangelou G: Factors associated with HIV seropositivity in European injecting drug users. AIDS 1993, 7:1485-1491.
19. Hartgers C, van Santen GW, van Haastrecht HJ, van den Hoek JAR, van Akker R, Coutinho RA: HIV prevalence among drug users in methadone treatment at the drug care facilities of the Municipal Health Service in Amsterdam [in Dutch]. T Soc Gezondheidsz 1992, 70:275-279.
20. . Papaevanselou G, Richardson SC: HIV prevalence and risk factors among injecting drug users in EC and COST countries. In AIDS Research at EC Level. Edited by Baert AE, Koch MA, Montagner L, Razquin MC, Tyrrel D. Amsterdam: IOS Press; 1995.
21. Barends W: Routine HIV testing in a Rotterdam methadone programme [in Dutch]. Medisch Contact 1988, 43:58-60.
22. Wiessing LG, Toet J, Houweling H, Koedijk PM, van den Akker R, Sprenger MJ: Prevalence and Risk Factors of HIV Infection Among Drug Users in Rotterdam. RIVM Report No. 21220001 [In Dutch]. Bilthoven: Rijksinstituut voor Volkgezondheid en Milieuhygiëne; 1996.
23. Käll KI, Olin RG: HIV status and changes in risk behaviour among intravenous drug users in Stockholm 1987-1988. AIDS 1990, 4:151-157.
24. Communicable Disease Surveillance Centre/Public Health Laboratory Service: Unlinked anonymous HIV prevalence monitoring programme in England and Wales: preliminary results. CDR Rev 1991, 1:R69-R76.
25. Noone A, Durante AJ, Brady AR, et al.: HIV infection in injecting drug users attending centres in England and Wales, 1990-1991. AIDS 1993, 7:1501-1507.
26. Communicable Disease Surveillance Centre/Public Health Laboratory Service: Unlinked anonymous monitoring of HIV prevalence in England and Wales: 1990-92. CDR Rev 1993, 3:R1-R11.
27. Communicable Disease Surveillance Centre/Public Health Laboratory Service: Unlinked Anonymous HIV Prevalence Steering Group. Unlinked Anonymous HIV Prevalence Monitoring Programme: England and Wales. Data to the End of 1994. London: Department of Health/PHLS/Institute of Child Health; December 1995.
28. Haw S, Frischer M, Donoghoe M, et al.: The importance of multisite sampling in determining the prevalence of HIV among drug injectors in Glasgow and London. AIDS 1992, 6:517-518.
29. Rhode's TJ, Bloor MJ, Donoghoe MC, et al.: HIV prevalence and HIV risk behaviour among injecting drug users in London and Glasgow. AIDS Care 1993, 5:413-425.
30. Stimson GV, Hunter GM, Donoghoe MC, Rhodes T, Parry JV, Chalmers CP: HIV-1 prevalence in community-wide samples of injecting drug users in London, 1990-1993. AIDS 1996, 10:657-666.
31. Peutherer JF, Edmond E, Simmonds P, Dickson JD, Bath GE: HTLV-III antibody in Edinburgh drug addicts. Lancet 1985, ii:1129-1130.
32. Skidmore CA, Robertson JR, Robertson AA, Elton R: After the epidemic: follow up of study of HIV seroprevalence and changing patterns of drug use. BMJ 1990, 300:219-223.
33. Richardson AM, Davies AG, Peters A, Dominy N: Serial prevalence study of HIV infection and HIV risk behaviour among injecting drug users in Edinburgh 1992-1994. ANSWER (AIDS News Supplement to the Weekly Report) 95/47. Glasgow: Scottish Centre for Infection and Environmental Health: 1995.
34. Laylor A, Frischer M, Green ST, Goldberg D, McKeganey N, Gruer L: Low and stable prevalence of HIV among drug injectors in Glasgow. Int J STD AIDS 1994, 5:105-107.
35. Frischer M, Leyland A, Cormack R, et al.: Estimating the population prevalence of injection drug use and infection with human immunodeficiency virus among injection drug users in Glasgow, Scotland. Am J Epidemiol 1993, 138:170-181.
36. Scottish Centre for Infection and Environmental Health: HIV and AIDS surveillance in Scotland. Review of the epidemic to December 1994. ANSWER (AIDS Supplement to the weekly Report). Glasgow: Scottish Centre for Infection and Environmental Health; 1995.
37. Goldberg D, Davis B, Allardice G, McMenamin J, Codere G: Monitoring the spread of HIV and AIDS in Scotland 1983-1994. Scott Med J 1996, 41:131-137.
38. Rezza G, De Rose A, Dorrucci M, Arpino C, Serafin I: Declining prevalence of HIV infection among injecting drug users entering drug treatment in Italy: 1990-1991. Eur J Epidemiol 1993, 9:663-666.
39. Lardelli P, De La Fuente L, Alonso JM, Lopez R, Bravo MJ, Delgado-Rodriguez M: Geographical variations in the prevalence of HIV infection among drug users receiving ambulatory treatment in Spain. Int J Epidemiol 1993, 22:306-314.
40. Centre for Epidemiological Studies on AIDS of Catalonia: Integrated system of HIV/AIDS epidemiological surveillance in Catalonia [in Spanish]. Annual Report 1995 (No. 2) Barcelona: ESCAT; 1995.
41. Federal Office for Public Health: AIDS and HIV in Switzerland: Epidemiological Situation by End of 1995. Liebefeld: Swiss Federal Office for Public Health; 1996.
42. Bruckova M: Characteristic features of HIV/AIDS in the Czech Republic. Central Eur J Public Health 1993, 1:79.
43. Klavs I, Kristancic L, Celan Lucu B, et al.: Results of unlinked anonymous HIV prevalence monitoring of pregnant women, STD patients and injecting drug users in Slovenia. XI International Conference on AIDS. Vancouver, July 1996 [abstract TU200].
44. Des Jarlais DC, Friedman SR, Choopanya K, Vanichseni S, Ward TP: International epidemiology of HIV and AIDS among injecting drug users. AIDS 1992, 6:1053-1068.
45. Rodrigo JM, Serra MA, Aguilar E, Del Olmo JA, Gimeno V, Aparisi L: HTLV-III antibodies in drug addicts in Spain. Lancet 1985, ii:156-157.
46. Ferroni P, Geroldi D, Galli C, Zanetti AR, Cargnel A: HTLV-III antibody among Italian drug addicts. Lancet 1985, ii:52-53.
47. Mortimer PP, Vandevelde EM, Jesson WJ, Pereira MS: HTLV-III antibodies in Swiss and English intravenous drug abusers. Lancet 1985, ii:449-450.
48. Angarano G, Pastore G, Monno L, Santantonio T, Luchena N, Schiraldi O: Rapid spread of HTLV-III infection among drug addicts in Italy [letter]. Lancet 1985, ii:1302.
49. Downs AM, Heisterkamp SH, Brunet JB, Hamers FF: Reconstruction and prediction of the HIV/AIDS epidemic among adults in the European Union and in the low prevalence countries of central and eastern Europe. AIDS 1997, 11:649-662.
50. Salvaggio A: Estimating the human immunodeficiency virus infection curve of intravenous drug users in Lombardy, Italy. Eur J Epidemiol 1995, 11:127-131.
51. Day NE: The incidence and prevalence of AIDS and prevalence of other severe HIV disease in England and Wales for 1995 to 1999: projections using data to end of 1994. CDR Res 1996, 6:R1-R24.
52. Zaccarelli M, Rezza G, Girardi E, Puro V, Pezzotti P, Narcisco P: Monitoring HIV trends in injecting drug users: an Italian experience. AIDS 1990, 4:1007-1010.
53. Romano N, Vitale F, Alesi DR, et al.: The changing pattern of human immunodeficiency virus type 1 infection in intravenous drug users. Am J Epidemiol 1992, 135:1189-1196.
54. Nicolosi A, Leite ML, Molinari S, Musicco M, Saracco A, Lazzarin A: Incidence and prevalence trends of HIV infection in intravenous drug users attending treatment centers in Milan and Northern Italy, 1986-1990. J Acquir Immun Defic Syndr 1992, 5:365-373.
55. van Ameijden EJ, van den Hoek JA, van Haastrecht HJ, Coutinho RA: The harm reduction approach and risk factors for human immunodeficiency virus seroconversion in injecting drug users, Amsterdam. Am J Epidemiol 1992, 135:1189-1196.
56. Ronald PJM, Robertson JR, Wyld R, Weightman R: Heterosexual transmission of HIV in injecting drug users. BMJ 1993 307:1184-1185.
57. Peters AD, Reid M, Griffi SG: Edinburgh drug users: are they injecting and sharing less? AIDS 1994, 8:521-528.
58. Broers B, Junet C, Gabriel V, et al.: Slow down of HIV epidemic among IDUs in Geneva, Switzerland. X International Conference on AIDS. Yokohama, July 1994 [abstract PCOI41].
59. Ronald PJ, Robertson JR: Prevalence of HIV infection among drug users in Edinburgh [letter]. BMJ 1992, 304:1506.
60. van Ameijden EJ, van den Hoek AR, Coutinho RA: Injecting risk behaviour among drug users in Amsterdam, 1986 to 1992, and its relationship to AIDS prevention programs. Am J Public Health 1994, 84:275-281.
61. Hunter GM, Donoghoe MC, Stimson GV, Rhodes T, Chalmers CP: Changes in the injecting risk behaviour of injecting drug users in London, 1990-1993. AIDS 1995, 9:493-501.
62. Desenclos JC, Papaevangelou G, Ancelle-Park R: Knowledge of HIV serostatus and preventive behaviour among European injecting drug users. AIDS 1993, 7:1371-1377.
63. Des Jarlais DC, Friedman SR, Friedmann P, et al.: HIV/AIDS-related behavior change among injecting drug users in different national settings. AIDS 1995, 9:611-617.
64. Robertson JR, Ronald PJ, Raab GM, Ross AJ, Parpia T: Deaths, HIV infection, abstinence, and other outcomes in a cohort of injecting drug users followed up for 10 years. BMJ 1994, 309:369-372.
65. . Stimpson GV, Chooponya K: Global perspectives on drug injecting. In Drug Injecting and HIV Infection: Global Dimensions and Local Responses. London: Taylor and Fracis/World Health Organization; 1997 (in press).
66. Hartnoll RL: Current situation relating to drug abuse assessment in European countries. Bull Narc 1986, 38:65-79.
67. Hartnoll R, Co-ordinator of the Pompidou Group (Co-operative Group to Combat Drug Abuse and Illicit Trafficking in Drugs): Multi-City Study: Drug Misuse Trends In Thirteen European Cities. Council to Europe (Pompidou Group). Strasbourg: Council of Europe Press; 1994.
68. Strang J, Des Jarlais DC, Griffiths P, Gossop M: The study of transitions in the route of drug use: the route from one route to another. Br J Addict 1992, 87:473-483.
69. Nicolosi A, Leite ML, Musicco M, Molinari S, Lazzarin A: Parenteral and sexual transmission of human immunodeficiency virus in intravenous drug users: a study of seroconversion. Am J Epidemiol 1992, 135:225-233.
70. Solomon L, Astemborski I, Warren D, et al.: Differences in risk factors for human immunodeficiency virus type 1 seroconversion among male and female intravenous drug users. Am J Epidemiol 1993, 137:892-898.
71. Watters JK, Estilo MJ, Kral AH, Lorvick JJ: HIV infection among female injection drug users recruited in community settings. Sex Transm Dis, 1994, 21:321-327.
72. Battjes RJ, Pickens RW, Brown LS: HIV infection and AIDS risk behaviors among injecting drug users entering methadone treatment: an update. J Acquir Immune Defic Syndr 1995, 10:90-96.
73. Wiebel W, Jimenez A, Johnson W, Ouellet I, Murray J, O'Brien M: Positive effect on HIV seroconversion of street outreach intervention with IDU in Chicago, 1988-1992. IX International Conference on AIDS. Berlin, June 1993 [abstract WS-C15-2].
74. Stephenson JM, Griffioen A: The effect of HIV diagnosis on reproductive experience. AIDS 1996, 10:1683-1687.
75. De Vincenzi I, Jadand C, Couturier E, et al.: Pregnancies and contraception in a French cohort of HIV-infected women. AIDS 1997, 11:333-338.
76. Ancelle-Park R, Alix J, Downs AM, Brunet JB, National Coordinators for AIDS Surveillance in 38 European countries: Impact of the 1993 revision of adult/adolescent AIDS surveillance case definition for Europe [letter]. Lancet 1995, 345:789-790.